clinical trial · NCT07840729
Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants
Shanghai JMT-Bio Inc.·phase1·recruiting·n = 90
Valid MeSH ConditiongsJMT206 injectionSemaglutide injectionPlacebo injection
brief summary
Use these resources to provide understandable information about this study to patients, families, and health care providers:
started
Oct 20, 2026
primary completion
Feb 28, 2027
completion
Apr 30, 2027
last updated
Nov 2, 2026
official title
Identify the Expanded Access Program, if Any. This is Required Unless the Expanded Access Type is "Individual Patients." A Randomized, Parallel, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JMT206 Injection Alone or in Combination With Semaglutide in Obese Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol